How Big Pharma Uses Charity Programs to Cover for Drug Price Hikes, bloomberg, May 19, 2016.
A billion-dollar system in which charitable giving is profitable for Big Pharma…
.
Press Play > to listen to the recording.
” In August 2015, Turing Pharmaceuticals and its then-chief executive, Martin Shkreli, purchased a drug called Daraprim and immediately raised its price more than 5,000 percent. Within days, Turing contacted Patient Services Inc., or PSI, a charity that helps people meet the insurance copayments on costly drugs. Turing wanted PSI to create a fund for patients with toxoplasmosis, a parasitic infection that is most often treated with Daraprim.
Having just made Daraprim much more costly, Turing was now offering to make it more affordable. But this is not a feel-good story. It’s a story about why expensive drugs keep getting more expensive, and how U.S. taxpayers support a billion-dollar system in which charitable giving is, in effect, a very profitable form of investing for drug companies—one that may also be tax-deductible. “…
…Continue reading: How Big Pharma Uses Charity Programs to Cover for Drug Price Hikes, bloomberg, May 19, 2016.